# ROSETTA CRC-203 (pumitamig): what one clinician is saying

> 7 statements from 5 sources (5 posts), 7 of them from 1 confirmed clinician, each linked to its source. Commentary checked Nov 16, 2026.

## Report

- Trial: ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- NCT ID: NCT07221357
- Registry: https://clinicaltrials.gov/study/NCT07221357
- Sponsor: Bristol-Myers Squibb
- Phase: Phase 2/Phase 3
- Status: Recruiting
- Drugs tested: pumitamig
- Indication: previously untreated, unresectable or metastatic colorectal cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-11-16 UTC
- Last checked: 2026-11-16 UTC
- Release hash: a4d0a35a78151783e42701a39b401474e2e5fb18fa1277435dc5ed0790f8147d

## Counts

- Commentary sources screened: 10
- Sources cited by verified statements: 5
- Verified statements: 7
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 7
- Findings: 3
- Named people in screened sources (unnamed speakers and accounts not counted): 1
- Speakers cited: 1
- Cited speakers with a verified identity: 1
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 1
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 1
- By role and specialty (the abstract's specialty counts):
  - 1 physician, specialty not confirmed

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

A physician described in the sources as serving on the ROSETTA CRC-203 steering committee sees scope for treatment change, reflecting expectations for bispecifics rather than reported benefit. They offered a referral route, but additional Latin American sites were only being discussed. Their forecast about anti-VEGF versus EGFR choices concerns future bispecific development, not evidence favoring either strategy. The statements do not assess benefit or safety or establish wider clinical agreement.

## Findings (titles)

- F1. ROSETTA in colorectal cancer: why a clinician sees potential to change care
  - 3 statements from 1 speaker in 3 sources.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 1 cited clinicians.
- F2. ROSETTA access: a clinician notes an open site and discusses Latin American expansion
  - 3 statements from 1 speaker in 3 sources.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 1 cited clinicians.

### Beyond the trial population

- F3. Anti-VEGF vs EGFR: a clinician sees a possible future rerun with bispecifics
  - 2 statements from 1 speaker in 1 source.
  - The one named speaker in this finding holds this view, a confirmed clinician.
  - 1 of the report's 1 cited clinicians.

1 of the 3 findings and 2 of the 7 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 3 | 3 | 3 | 1 | 2 |
| F2 | 3 | 3 | 3 | 1 | 2 |
| F3 | 2 | 1 | 1 | 1 | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 3 | 0 | 0 | 0 | 0 | 3 | 0 | 3 posts and articles |
| F2 | 1 | 0 | 1 | 0 | 1 | 4 | 0 | 3 posts and articles |
| F3 | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 1 post or article |

### Trial dimensions

- Primary endpoint: Objective Response (OR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessment: no finding draws on it directly
- Primary endpoint: Progression Free Survival (PFS) by RECIST v1.1 per blinded independent central review (BICR): no finding draws on it directly
- Primary endpoint: Overall Survival (OS): no finding draws on it directly
- Secondary endpoints: no finding draws on it directly
- Population and setting: F1 (1 shared claims), F2 (1 shared claims)
- The comparison: F1 (1 shared claims), F2 (1 shared claims)
- Safety and tolerability: no finding draws on it directly
- Design and conduct: F2 (1 shared claims)

## Abbreviations

- BICR: blinded independent central review
- CR: complete response
- CRC: colorectal cancer
- EGFR: epidermal growth factor receptor
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- OS: overall survival
- PFS: progression-free survival
- PR: partial response
- RECIST: Response Evaluation Criteria in Solid Tumors

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 3 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 7 | Paid |
| Who said each statement: the cited speakers | 1 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 1 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 1 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 11 | Free |
| Sources with links | 5 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 1 of the 1 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

6 discussed · 5 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Objective Response (OR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessment | no commentary found | 0 | 0 |
| Primary endpoint: Progression Free Survival (PFS) by RECIST v1.1 per blinded independent central review (BICR) | no commentary found | 0 | 0 |
| Primary endpoint: Overall Survival (OS) | no commentary found | 0 | 0 |
| Secondary endpoints | no commentary found | 0 | 0 |
| Population and setting | discussed | 4 | 3 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 2 | 2 |
| Safety and tolerability | no commentary found | 0 | 0 |
| Design and conduct | discussed | 2 | 2 |
| Expected clinical impact | discussed | 3 | 3 |
| Trial access, referral and geographic expansion | discussed | 3 | 3 |
| Future bispecific treatment positioning | discussed | 2 | 1 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Posts · 7 statements · 100%** | | | |
| X threads | 7 | 5 | 9 |
| Bluesky threads | 0 | 0 | 1 |

- Screened window: 2025-11-05 to 2026-08-31
- Cited window: 2026-02-27 to 2026-05-15
- Retrieved: 2026-11-16

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Registry: NCT07221357 (https://clinicaltrials.gov/study/NCT07221357)
- Study IDs: CA266-0003 · 2025-523224-45 (EU CT Number) · U1111-1325-6505 (UTN)
- Sponsor: Bristol-Myers Squibb
- Collaborators: BioNTech SE
- Design: Phase 2/Phase 3 · interventional, randomized, parallel, phase2, phase3
- Status: Recruiting
- Enrollment: 990 (estimated)
- Start: 2025-12-31 (actual)
- Primary completion: 2030-02-02 (estimated)
- Primary endpoint: Objective Response (OR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessment (Up to 5 years)
- Primary endpoint: Progression Free Survival (PFS) by RECIST v1.1 per blinded independent central review (BICR) (Up to 5 years)
- Primary endpoint: Overall Survival (OS) (Up to 5 years)
- Intervention: Pumitamig (drug)
- Intervention: FOLFOX (drug)
- Intervention: FOLFIRI (drug)
- Intervention: Bevacizumab (drug)
- Intervention: CAPOX (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 2 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 39 sources about other trials or topics are not included.
- The substantive views come from one X author, described in the sources as on the ROSETTA CRC-203 steering committee. Multiple posts and reposts do not establish independent endorsement or wider HCP agreement.
- Discussion that does not explicitly name the trial, or uses other naming variants, may be missing, limiting conclusions about the breadth of HCP opinion.
- No exact-trial publication or full protocol was identified for this edition. The cited statements do not evaluate response, progression-free survival, overall survival, safety or detailed patient selection.
- Site-access statements describe the circumstances reported on the post dates. Proposed Latin American expansion should not be read as confirmation that additional centers opened.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-16 UTC: current edition
  - Routine maintenance: 1 fix (tags):
    - 2026-11-18 UTC: taxonomy mapping corrected

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-16 UTC. No changes.

## Offer

- Size: Focused · 7 verified statements · 7 from 1 confirmed clinician
- Not for sale: This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it, by any route; a later edition that reaches the minimum is for sale at its normal price. Follow the change feed: https://www.erudio.com/reports/rosetta-crc-203-nct07221357/feed.json
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=rosetta-crc-203-nct07221357

## Cite

Erudio Health. ROSETTA CRC-203 (NCT07221357): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 16, 2026. https://www.erudio.com/reports/rosetta-crc-203-nct07221357

## Questions

### How much does the ROSETTA CRC-203 report cost?

This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested.

### What does the ROSETTA CRC-203 report cover?

7 statements from 5 sources (5 posts), 7 of them from 1 confirmed clinician, each linked to its source. Commentary checked Nov 16, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the ROSETTA CRC-203 report?

Its preview, yes: get_report_card({ "slug": "rosetta-crc-203-nct07221357" }) on https://mcp.erudio.com/free, with no sign-in. It cannot be ordered yet. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the ROSETTA CRC-203 report?

Edition 1 (version 1.0.0), accepted Nov 16, 2026 UTC; last checked for new commentary Nov 16, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/rosetta-crc-203-nct07221357.json
- Markdown: https://www.erudio.com/reports/rosetta-crc-203-nct07221357.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/rosetta-crc-203-nct07221357/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "rosetta-crc-203-nct07221357"}`
